UCB, Novartis ink German licensing deal

UCB is expanding in Germany with a new Novartis licensing agreement for cardiovascular and diabetes products. UCB gains extended commercial rights to the cardio drug medication Provas beyond 2011. The Belgian drugmaker also gets commercial rights for two line extensions: the hypertension drugs Dafiro and Dafiro HCT. Finally, UCB and Novartis will co-commercialize the two new oral anti-diabetics, Jalra and Icandra.

A spokesperson for the company said the deal helps UBC build its business in Germany, which is UCB's second-largest market. UCB Germany, which focuses on the fields of central nervous system, immunology disorders and internal medicine, employs about 1,400 people. Financial details of the deal were not disclosed.

- see UCB's release
- read the article from Reuters

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.